[go: up one dir, main page]

DE69603681D1 - Verwendung mindestens eines beta-adrenergen Agonisten als Antagonist der Substanz P - Google Patents

Verwendung mindestens eines beta-adrenergen Agonisten als Antagonist der Substanz P

Info

Publication number
DE69603681D1
DE69603681D1 DE69603681T DE69603681T DE69603681D1 DE 69603681 D1 DE69603681 D1 DE 69603681D1 DE 69603681 T DE69603681 T DE 69603681T DE 69603681 T DE69603681 T DE 69603681T DE 69603681 D1 DE69603681 D1 DE 69603681D1
Authority
DE
Germany
Prior art keywords
antagonist
beta
substance
adrenergic agonist
adrenergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69603681T
Other languages
English (en)
Other versions
DE69603681T2 (de
Inventor
Lionel Breton
Lacharriere Olivier De
Jacques Leclaire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of DE69603681D1 publication Critical patent/DE69603681D1/de
Application granted granted Critical
Publication of DE69603681T2 publication Critical patent/DE69603681T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69603681T 1995-10-23 1996-10-01 Verwendung mindestens eines beta-adrenergen Agonisten als Antagonist der Substanz P Expired - Fee Related DE69603681T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9512447A FR2740040B1 (fr) 1995-10-23 1995-10-23 Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p

Publications (2)

Publication Number Publication Date
DE69603681D1 true DE69603681D1 (de) 1999-09-16
DE69603681T2 DE69603681T2 (de) 1999-11-25

Family

ID=9483809

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69603681T Expired - Fee Related DE69603681T2 (de) 1995-10-23 1996-10-01 Verwendung mindestens eines beta-adrenergen Agonisten als Antagonist der Substanz P

Country Status (14)

Country Link
US (2) US5958432A (de)
EP (1) EP0769293B1 (de)
JP (1) JP3636473B2 (de)
AR (1) AR004052A1 (de)
BR (1) BR9611302A (de)
CA (1) CA2222311C (de)
DE (1) DE69603681T2 (de)
DK (1) DK0769293T3 (de)
FR (1) FR2740040B1 (de)
HU (1) HUP9900511A3 (de)
NO (1) NO312273B1 (de)
PL (1) PL186366B1 (de)
RU (1) RU2169552C2 (de)
WO (1) WO1997015281A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948972A (en) * 1994-12-22 1999-09-07 Kla-Tencor Corporation Dual stage instrument for scanning a specimen
US6503953B2 (en) 2000-07-26 2003-01-07 Atopic Pty Ltd. Methods for treating atopic disorders
ITPD20010187A1 (it) * 2001-07-23 2003-01-23 Cutech Srl Trattamento del follicolo polifero, in particolare contro la caduta dei capelli
EP1295599A1 (de) * 2001-09-21 2003-03-26 Boehringer Ingelheim International GmbH Verfahren zur Behandlung oder Verhütung von atopischer Dermatitis
US20030219573A1 (en) * 2002-03-27 2003-11-27 Torgny Falk Absorbent product
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
RU2220738C1 (ru) * 2002-08-30 2004-01-10 Гапонюк Петр Яковлевич Средство для лечения ринита
US8343519B2 (en) * 2003-02-19 2013-01-01 L'oreal S.A. Chemical enhancer and method
US20040209850A1 (en) * 2003-04-15 2004-10-21 Theraquest Biosciences, Llc Methods of treating pain and compositions for use therefor
WO2006054513A1 (ja) * 2004-11-19 2006-05-26 Kissei Pharmaceutical Co., Ltd. 神経因性疼痛の予防又は治療剤
JP5021621B2 (ja) 2005-04-13 2012-09-12 アスション ファーマ エー／エス 皮膚の結合組織病を治療するためのβ−２アドレナリン受容体作動薬
ES2375924T3 (es) * 2008-01-18 2012-03-07 Centre National De La Recherche Scientifique - Cnrs Agonistas beta-2 adrenérgicos para su utilización en el tratamiento de la alodinia neurop�?tica crónica.
GB0805535D0 (en) 2008-03-27 2008-04-30 Univ Leicester Scar prevention
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
AU2010217615C1 (en) * 2009-02-24 2013-05-23 Novartis Ag Uses of NK receptor antagonists
GB2513297A (en) 2013-03-08 2014-10-29 Univ Leicester Methods
US9937117B2 (en) 2015-07-09 2018-04-10 Galderma S.A. Method of reducing hair loss associated with chemotherapy
JP7152051B2 (ja) * 2018-05-29 2022-10-12 株式会社ナノエッグ アトピー性皮膚炎を治療または予防するための組成物
WO2020051568A1 (en) * 2018-09-08 2020-03-12 Wen Tan NEW USE OF R-ENANTIOMER OF ADRENERGIC β2 RECEPTOR AGONISTS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND ITS EXTRA INTESTINAL MANIFESTATIONS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1474316A (en) * 1975-02-12 1977-05-25 Seperic O-aminoalkyl oximes
US4038417A (en) * 1975-06-19 1977-07-26 Nelson Research & Development Company Method for treatment of psoriasis
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US5366731A (en) * 1990-08-24 1994-11-22 Wisconsin Alumni Research Foundation Cosmetic compositions containing secosterol compounds
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
CA2114968A1 (en) * 1993-02-25 1994-08-26 John Wille Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
JPH07258067A (ja) * 1994-03-18 1995-10-09 Kao Corp 浴用剤組成物
FR2719474B1 (fr) * 1994-05-05 1996-05-31 Oreal Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.

Also Published As

Publication number Publication date
EP0769293B1 (de) 1999-08-11
JP2000503628A (ja) 2000-03-28
MX9710475A (es) 1998-08-30
NO312273B1 (no) 2002-04-22
PL186366B1 (pl) 2003-12-31
EP0769293A3 (de) 1997-05-02
CA2222311A1 (fr) 1997-05-01
BR9611302A (pt) 1999-03-30
AR004052A1 (es) 1998-09-30
CA2222311C (fr) 2006-11-28
PL324924A1 (en) 1998-06-22
US5958432A (en) 1999-09-28
WO1997015281A1 (fr) 1997-05-01
DE69603681T2 (de) 1999-11-25
NO976143D0 (no) 1997-12-30
EP0769293A2 (de) 1997-04-23
NO976143L (no) 1998-06-03
HUP9900511A3 (en) 2000-09-28
US6267972B1 (en) 2001-07-31
FR2740040B1 (fr) 1997-12-05
JP3636473B2 (ja) 2005-04-06
RU2169552C2 (ru) 2001-06-27
HUP9900511A2 (hu) 1999-07-28
FR2740040A1 (fr) 1997-04-25
DK0769293T3 (da) 1999-12-06

Similar Documents

Publication Publication Date Title
DE69603681D1 (de) Verwendung mindestens eines beta-adrenergen Agonisten als Antagonist der Substanz P
NO960081L (no) Östrogen-agonist/antagonister
NO964871D0 (no) Nye agonistforbindelser
DE69627179T2 (de) Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren
EA199700280A1 (ru) Ингибиторы протеинкиназы с
DE69520032D1 (de) Topische Zusammensetzung enthaltend ein Antagonist der Substanz P
BR9206237A (pt) Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1.
NO983181L (no) Nye substituerte imidazolforbindelser
NO996572L (no) Nye substituerte imidazolforbindelser
ATE160934T1 (de) Verwendung eines antagonisten der substanz p in einer topischen zusammensetzung als antitranspirationsmittel
FI960516A7 (fi) Substituoituja bifenyylisulfonamidiendoteliiniantagonisteja
EE04141B1 (et) 5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga
NO974605D0 (no) Nye heterosykliske forbindelser
BR9709030A (pt) Compensação de nível de liquido para um cilindro emissor
EP1095316A4 (de) Dynamische verbrauchsermittlung
BR9505382A (pt) Utilização de ao menos um antagonista de substáncia P
DE69622731D1 (de) Tetrahydrochinoline als nmda antagonisten
DE69431201D1 (de) Verwendung von indolderivaten als 5ht1-agonisten
DE69530007D1 (de) Prüfen der oberfläche eines objekts
DE69707098D1 (de) Substituierte tetralylmethylenoxindol-analoga als tyrosinkinase-inhibitoren
DE69432936D1 (de) Betriebsüberwachungseinrichtung eines elektrophotographischen Gerätes
BR9505392A (pt) Utilizações de ao menos um antagonista de substância P
BR9605033A (pt) Sonda digitalizada
FI103672B1 (fi) Menetelmä aineen vaikutusten arvioimiseksi in vitro
NO981216D0 (no) Nye heterosykliske forbindelser

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee